By Kathryn Hardison

Shares of Moderna Inc. gained 4.8% to $199.85 in after-hours trading Tuesday after the drugmaker said an experimental vaccine significantly reduced the risk of a viral respiratory disease among older adults in a large clinical trial.

The stock ended the regular session down 0.7% at $190.69.

The Cambridge, Mass.-based company said its vaccine for respiratory syncytial virus was 83.7% effective against lower-respiratory diseases caused by the virus in the recent study. In more severe cases, Moderna's vaccine was 82.4% effective at preventing RSV cases with three or more symptoms present, the company said.

Moderna plans to apply in the coming months for U.S. regulatory approval to sell the vaccine. If regulators approve, it could become available by early 2024, the company said.

Write to Kathryn Hardison at kathryn.hardison@wsj.com

(END) Dow Jones Newswires

January 17, 2023 16:54 ET (21:54 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Mai 2023 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mai 2022 até Mai 2023 Click aqui para mais gráficos Moderna.